6533b832fe1ef96bd129aead
RESEARCH PRODUCT
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop
Teresa PollicinoMassimo ColomboAlfredo MarzanoPietro LamperticoGiovanni RaimondoFrancesco MazzottaMaurizia Rossana BrunettoGiampiero CarosiMario RizzettoMario TotiGiovanni Battista GaetaFelice PiccininoGiuseppe PastoreEvangelista SagnelliVito Di MarcoDaniele PratiMassimo LevreroCarlo FerrariAntonio CraxìMassimo PuotiAlfredo AlbertiAntonina SmedileGaetano FiliceRaffaele BrunoTeresa SantantonioGiuseppe Caritisubject
Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drugdescription
Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the indication to follow either strategy is also based on the stage of liver fibrosis; (d) virological monitoring is modified to include the definitions of failure and of sustained virological response to interferon therapy; (e) the recommendation to use HBV DNA assays with high sensitivity and wide linear ranges is underlined (f) guidelines on post-treatment follow-up after finite treatment with NA, potential side effects of therapy and non-virological monitoring are defined; (g) definitions and treatment of patients without optimal response to NA are reported; (f) treatment and monitoring of compensated or decompensated cirrhosis and hepatocellular carcinoma are updated.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-01-01 |